Pancreatic Cancer Research

ResearcherUniversity of LouisvilleActive in the last 2 years

Charles Raben Scoggins

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108711339. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 4 papers · 2025: 2 papers · 2026: 1 paper

Papers 22

  1. Evaluation of radiomics and radiologic signatures for diagnosis and clinical outcomes in pancreatic adenocarcinoma and pancreatic neuroendocrine: A pilot study. Co-author DOI 10.1177/18758592261455545↗
  2. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  3. Detection of Exhaled Volatile Organic Compounds as Noninvasive Biomarkers for Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-025-17685-z↗
  4. Barriers to resection following neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma: A national and local perspective. Co-author DOI 10.1002/jso.27697↗
  5. Multi-institutional review of adverse events associated with irreversible electroporation in the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.08.042↗
  6. Diagnosis of Pancreatic Cancer after Cholecystectomy in the Elderly. Co-author DOI 10.1177/00031348241227165↗
  7. Optimization of Exocrine Pancreatic Insufficiency in Pancreatic Adenocarcinoma Patients. First author DOI 10.3390/nu16203499↗
  8. Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer. Last author DOI 10.1016/j.surg.2022.07.033↗
  9. Locally advanced pancreatic cancer: a reliable contraindication to resection in the modern era? Co-author DOI 10.1016/j.hpb.2021.09.002↗
  10. An Improved Staging System for Locally Advanced Pancreatic Cancer: A Critical Need in the Multidisciplinary Era. Co-author DOI 10.1245/s10434-021-10174-z↗
  11. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  12. Gastric Electrical Stimulation Is an Effective Treatment Modality for Refractory Gastroparesis in a Postsurgical Patient with Pancreatic Cancer. Co-author DOI 10.1159/000503275↗
  13. Splenic Preservation Just Might Be Reasonable for Patients with Left-Sided Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-07124-7↗
  14. Efficacy of preoperative immunonutrition in locally advanced pancreatic cancer undergoing irreversible electroporation (IRE). Co-author DOI 10.1016/j.ejso.2017.01.002↗
  15. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Co-author DOI 10.1097/sla.0000000000001441↗
  16. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-ins… Co-author DOI 10.1007/s11605-014-2567-4↗
  17. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  18. The role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery. Co-author DOI 10.1111/hpb.12306↗
  19. Tumor-positive resection margins reflect an aggressive tumor biology in pancreatic cancer. Last author DOI 10.1002/jso.23299↗
  20. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. Last author DOI 10.1111/j.1477-2574.2011.00432.x↗
  21. Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer. Last author DOI 10.1007/s11605-011-1448-3↗
  22. Is prior cholecystectomy associated with decreased survival in patients with resectable pancreatic adenocarcinoma following pancreaticoduodenectomy? Co-author DOI 10.1016/j.amjsurg.2010.02.004↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert C.G. Martin · 20 shared papers, 2011–2026 · strength 2.68
  2. Prejesh Philips · 11 shared papers, 2014–2026 · strength 2.18
  3. Michael E. Egger · 9 shared papers, 2021–2026 · strength 2.05
  4. Marc W. Fromer · 5 shared papers, 2021–2026 · strength 1.08
  5. Kyle R Stephens · 2 shared papers, 2024–2025 · strength 0.47
  6. Syed Ameen Ahmad · 6 shared papers, 2011–2025 · strength 0.37
  7. Sharon Marie Weber · 6 shared papers, 2011–2025 · strength 0.37
  8. Nipun B. Merchant · 5 shared papers, 2012–2025 · strength 0.35
  9. Jacob W. H. Gordon · 1 shared paper, 2026 · strength 0.33
  10. Daniel Erik Abbott · 4 shared papers, 2014–2025 · strength 0.33
  11. Shishir Kumar Maithel · 4 shared papers, 2014–2025 · strength 0.33
  12. Jaclyn V. Moore · 1 shared paper, 2024 · strength 0.28
  13. Alexander A. Parikh · 4 shared papers, 2012–2025 · strength 0.28
  14. Sameer H. Patel · 2 shared papers, 2019–2025 · strength 0.27
  15. David A. Kooby · 6 shared papers, 2011–2019 · strength 0.20
  16. Benjamin A. Y. Cher · 1 shared paper, 2025 · strength 0.19
  17. Rebecca Anne Snyder · 1 shared paper, 2025 · strength 0.19
  18. Mihir Maheshkumar Shah · 1 shared paper, 2025 · strength 0.19
  19. Chet W. Hammill · 1 shared paper, 2025 · strength 0.19
  20. Jashodeep Datta · 1 shared paper, 2025 · strength 0.19
  21. William G. Hawkins · 3 shared papers, 2012–2019 · strength 0.12
  22. Shreyans Doshi · 1 shared paper, 2019 · strength 0.11
  23. Thomas L. Abell · 1 shared paper, 2019 · strength 0.11
  24. Emily R. Winslow · 4 shared papers, 2011–2014 · strength 0.11
  25. Ryan C Fields · 2 shared papers, 2014–2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.